Amundi’s ChemoCentryx, Inc. CCXI Stock Holding History

Amundi’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,900	Closed	-$79K	–	1656
2021 Q2	$79K	Buy	+5,900	New	+$145K	﹤0.01%	1464

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Amundi's CCXI Position: Q3 2021 in Review

Amundi sold out of ChemoCentryx, Inc. (CCXI) in Q3 2021, closing a stake of 5,900 shares — an estimated $79K sold.

Amundi first reported a position in CCXI in Q2 2021 and held it in 1 quarter. The position peaked at $79K in Q2 2021. 140 funds tracked by Wall St. Rank hold CCXI as of Q3 2021.

Amundi reported no remaining ChemoCentryx, Inc. position as of Q3 2021 after selling out during the quarter.
Amundi sold 5,900 ChemoCentryx, Inc. shares in Q3 2021, an estimated $79K.
Amundi first reported a position in ChemoCentryx, Inc. in Q2 2021 and held it in 1 quarter.
Amundi's ChemoCentryx, Inc. position peaked at $79K in Q2 2021.
140 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2021.

Based on Amundi's 13F filing for Q3 2021, filed 15 Nov 2021.